119 related articles for article (PubMed ID: 19748423)
1. Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Duffull SB; Landersdorfer CB; Kinzig M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):130-41. PubMed ID: 19748423
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Landersdorfer CB; Hüttner SJ; Drusano GL; Kinzig M; Holzgrabe U; Stephan U; Sörgel F
Antimicrob Agents Chemother; 2010 Mar; 54(3):1275-82. PubMed ID: 20065059
[TBL] [Abstract][Full Text] [Related]
3. Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Kinzig M; Landersdorfer CB; Holzgrabe U; Stephan U; Sörgel F
Antimicrob Agents Chemother; 2011 Jun; 55(6):2927-36. PubMed ID: 21402834
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
Mouton JW; Punt N; Vinks AA
Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
[TBL] [Abstract][Full Text] [Related]
5. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
Bulitta JB; Duffull SB; Kinzig-Schippers M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2007 Jul; 51(7):2497-507. PubMed ID: 17485505
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.
Vinks AA; van Rossem RN; Mathôt RA; Heijerman HG; Mouton JW
Antimicrob Agents Chemother; 2007 Sep; 51(9):3049-55. PubMed ID: 17576827
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.
Landersdorfer CB; Kirkpatrick CM; Kinzig-Schippers M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2007 Sep; 51(9):3290-7. PubMed ID: 17576847
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.
Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2016 Jan; 71(1):189-95. PubMed ID: 26416780
[TBL] [Abstract][Full Text] [Related]
9. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.
Autry EB; Rybak JM; Leung NR; Gardner BM; Burgess DR; Anstead MI; Kuhn RJ
Pharmacotherapy; 2016 Jan; 36(1):13-8. PubMed ID: 26748559
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
[TBL] [Abstract][Full Text] [Related]
16. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
[TBL] [Abstract][Full Text] [Related]
17. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
[TBL] [Abstract][Full Text] [Related]
18. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
[TBL] [Abstract][Full Text] [Related]
19. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
Kim A; Kuti JL; Nicolau DP
Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers.
Wiskirchen DE; Housman ST; Quintiliani R; Nicolau DP; Kuti JL
Pharmacotherapy; 2013 Mar; 33(3):266-74. PubMed ID: 23400916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
